1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

China Approves World’s First Recombinant Botulinum Toxin: A Break from Tradition

30 Apr 2026
Admin
News Article

China Approves World’s First Recombinant Botulinum Toxin: A Break from Tradition

A quiet but meaningful shift just happened in the neurotoxin space.

National Medical Products Administration (NMPA) has approved Retoxin®—the world’s first recombinant botulinum toxin type A—developed by Chongqing Claruvis Pharmaceutical Co., Ltd..

The initial indication: temporary improvement of moderate to severe glabellar lines in adults.

Why This Approval Is Different

Botulinum toxin products have traditionally relied on extraction from Clostridium botulinum. Retoxin® flips that model.

First recombinant (genetically engineered) botulinum toxin
Moves away from biological extraction
Built using controlled, precision manufacturing

This isn’t just another aesthetic injectable. It’s a platform shift.

From Natural Extraction to Precision Engineering

Claruvis has built Retoxin® on a proprietary recombinant platform.

Here’s what that changes:

Preserved molecular structure: Maintains the core 150 kDa neurotoxin architecture
Higher purity: Reduced contamination risks compared to extraction-based methods
Improved safety profile: Eliminates biosafety concerns tied to bacterial sourcing
High specific activity: Potential for more consistent clinical performance

In simple terms: tighter control, cleaner product, fewer variables.

Clinical Performance: What the Data Shows

In a Phase III trial conducted in China, Retoxin® delivered across the board:

Met all primary and secondary endpoints
Demonstrated superior efficacy
Showed favorable safety profile
Reported low immunogenicity

The study design—multicenter, randomized, double-blind, placebo- and active-controlled—adds credibility to the results.

Beyond Aesthetics: Expanding into Therapeutics

Claruvis isn’t stopping at cosmetic use. Retoxin® is also being developed for:

Upper limb spasticity in adults
Conditions linked to stroke or traumatic brain injury

Current status:

Phase II trial completed
Phase III trial underway across 20+ sites in China

This signals a broader ambition: compete in both aesthetic and neurological indications.

What This Means for the Industry?

This approval introduces a new competitive axis.

1. Manufacturing Innovation Becomes a Differentiator

Recombinant production could redefine quality benchmarks in botulinum toxins.

2. Safety and Consistency Take Center Stage

Reduced variability and biosafety risks may influence regulatory expectations globally.

3. Pipeline Expansion Gets Easier

A recombinant platform opens the door to multiple indications with a single core technology.

Leadership Perspective

According to Claruvis leadership:

Retoxin® validates their recombinant platform strategy
The company is building a broader portfolio of next-gen neurotoxins
Focus remains on both therapeutic and aesthetic applications

Translation: this is the first step, not the endgame.

About Chongqing Claruvis Pharmaceutical Co., Ltd.

A subsidiary of MingMed Biotechnology, Claruvis focuses on recombinant botulinum toxin development—from R&D to commercialization. The company is positioning itself as a pioneer in transitioning the industry from extraction-based methods to engineered biologics.

Bottom Line

Retoxin® is more than a product launch. It’s proof that botulinum toxin manufacturing can evolve.

First recombinant approval globally
Strong clinical backing
Expansion into high-value therapeutic areas

If this platform scales, traditional botulinum toxin players may need to rethink how their products are made—and how they compete.